Our Pipeline

Currently, four Inhibrx programs are in ongoing clinical trials: three for the treatment of various cancers, and one for Alpha-1 Antitrypsin Deficiency (AATD). Additionally, INBRX-121 is our newest preclinical program currently in cell line development.

The Candidates

Preclinical
Phase 1
Phase 2
Phase 3

INBRX-101

Our Recombinant Alpha-1 Anti- trypsin Fc-Fusion Protein (AAT-Fc)

Orphan / Respiratory

INBRX-101 is a recombinant human AAT-Fc fusion protein therapeutic candidate currently being evaluated for the treatment of AATD. Early clinical data has demonstrated a promising pharmacokinetic profile that we believe supports a dosing schedule of every three weeks to achieve continuous normal AAT serum concentrations, a significant improvement from patients’ current regimen.

Learn more clinicaltrials.gov
Inbrx 101

INBRX-109

Our Tetravalent DR5 Agonist

Oncology

INBRX-109 is a precisely engineered tetravalent sdAb-based therapeutic candidate that agonizes DR5 to induce tumor selective programmed cell death.

Learn more Phase 1 Trial
Inbrx 109

INBRX-106

Our Hexavalent OX40 Agonist

Oncology

INBRX-106 is a hexavalent sdAb-based therapeutic candidate targeting OX40 currently being evaluated in patients with locally advanced or metastatic solid tumors. Signaling through OX40 provides co-stimulation that promotes T-cell expansion, enhanced effector function and memory cell formation, and prevents activation-induced cell death.

Learn more clinicaltrials.gov
Inbrx 106

INBRX-105

Our PD-L1 x 4-1BB Tetravalent Conditional Agonist

Oncology

INBRX-105 is a tetravalent sdAb-based therapeutic candidate currently being evaluated in patients with programmed death ligand 1 (PD-L1) expressing tumors, including those refractory to, or relapsed from, approved checkpoint inhibitor therapies. INBRX-105 is designed to agonize 4-1BB selectively in the presence of PD-L1.

Learn more clinicaltrials.gov
Inbrx 105

INBRX-121

Our NKp46 Targeted Detuned IL-2

Preclinical

INBRX-121 is the first program to be borne from our Molecular Targeted Cytokine (MTC) Platform, which combines our sdAb platform with a proprietary detuned cytokine to enable expansion of specific cell populations.

Learn more
Inbrx 121

Near-term Clinical Milestones

Milestones Graphic Lg

1. INBRX-105 (PD-L1 x 41BB) Keytruda dose escalation data

2. INBRX-101 (AAT) Additional Phase 1 data

3. INBRX-106 (OX40) / Keytruda initial dose expansion cohort data

4. INBRX-109 (DR5) Initial mesothelioma, Ewing sarcoma, pancreatic cancer, and colorectal cancer combination study data

5. INBRX-101 (AAT) Potential start to registration study

6. INBRX-121 (IL-2) IND filing

7. INBRX-105 (PD-L1 x 41BB) Keytruda dose expansion cohort data